Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer

Neoadjuvant chemotherapy is now considered standard of care for most of the patients with clinically node-positive disease, and for a large proportion of triple-negative breast cancer and HER2-positive tumors. Here we reviewed the benefit of neoadjuvant chemotherapy on surgical de-escalation, the prognostic role of pathologic complete response, new therapeutic strategies across subtypes, and ongoing studies assessing locoregional treatment de-escalation according to treatment response. Thanks to the integration of new biomarkers, new ways to detect minimal residual disease after neoadjuvant chemotherapy, and new targeted therapies, the landscape of neoadjuvant therapy is evolving rapidly, and our ability to personalize breast cancer treatment is improving.